By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genomic test development firm Med BioGene today reported revenues of $593,714 for the first half of 2011, compared to no revenues in the year-ago period.

All revenues during the six months ended June 30 were generated from licensing deals.

For the half-year, the Vancouver, British Columbia-based firm posted net income of $215,034, or break-even on an EPS basis, compared to a loss of $1 million, or $.01 per share, for the first half of 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.